Skip to main content

Advertisement

SpringerLink
Log in

Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Although Ras-association domain family of gene 2 (RASSF2) has been shown to undergo promoter methylation at high frequency in some cancer types and in brain metastases, its clinical utility as a useful prognostic molecular marker remains unclear in gastric cancer.

Methods

Prognostic significance of RASSF2 expression was retrospectively analysed by immunohistochemically in 105 patients with gastric cancer who underwent curative gastrectomy.

Results

Low RASSF2 expression was detected in 58 (55 %) patients, whereas 47 patients (45 %) had high RASSF2 expression. Lymph node involvement, pT stage, TNM stage, vascular invasion, perineural invasion and the presence of recurrence were found to be significantly related to RASSF2 expression levels. Low PRL-3 expression was closely correlated with lymph node metastasis (p = 0.001), advanced pT stage (p = 0.021), advanced TNM stage (p < 0.001), the presence of vascular invasion (p < 0.001), perineural invasion (p = 0.018) and high prevalence of recurrence (p = 0.003) compared with high RASSF2 expression. The median disease-free survival (DFS) time for patients with low RASSF2 expression was significantly worse than that of patients with high RASSF2 expression (10.2 vs. 50.6 months, p < 0.001). In addition, patients with high RASSF2 expression had the higher overall survival (OS) interval compared to patients with low RASSF2 expression (NR vs. 14.9 months, p < 0.001). In the multivariate analysis, the rate of RASSF2 expression levels was an independent prognostic factor, for DFS [p < 0.001, HR 0.12 (0.10–0.88)] and OS [p < 0.001, HR 0.10 (0.04–0.46)], as were pT stage and TNM stage, respectively.

Conclusions

RASSF2 may be an important molecular marker for carcinogenesis, prognosis and progression in gastric cancer, but the potential value of RASSF2 expression as a useful molecular marker in gastric cancer progression should be evaluated, comprehensively. It would be possible to develop treatments targeting RASSF2 and advance new treatment strategies for gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16:84–93.

    Article  CAS  PubMed  Google Scholar 

  4. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24:2360–4.

    Article  CAS  PubMed  Google Scholar 

  5. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.

    Article  CAS  PubMed  Google Scholar 

  6. Liu C, Pan Y, Wang X, Lu J, Huang B, Li X. Activation of RASSF2A by p300 induces late apoptosis through histone hyperacetylation. Cell Biol Int. 2010;34:1133–9.

    Article  CAS  PubMed  Google Scholar 

  7. Luo D, Ye T, Li TQ, Tang P, Min SD, Zhao GF, et al. Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med. 2012;3:391–6.

    PubMed  PubMed Central  Google Scholar 

  8. Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene. 2009;28:2988–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796:114–28.

    CAS  PubMed  Google Scholar 

  10. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BS, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem. 2003;2(78):28045–51.

    Article  Google Scholar 

  11. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, et al. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene. 2008;27:1805–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene. 2005;24:3987–94.

    Article  CAS  PubMed  Google Scholar 

  13. Liao X, Siu MK, Chan KY, Wong ES, Ngan HY, Chan QK, et al. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer. 2008;123:296–302.

    Article  CAS  PubMed  Google Scholar 

  14. Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, et al. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis. 2008;29:1312–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer. 2010;9:264.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhang X, Ma Y, Wu Y, Lin L, Ma X, Zhang Y. Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer. J Obstet Gynaecol Res. 2014;40:1375–81.

    Article  CAS  PubMed  Google Scholar 

  17. Edge SB, Byrd DR, Compton CC. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010. p. 117.

    Google Scholar 

  18. Association Japanese Gastric Cancer. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer. 1998;1:10–24.

    Article  Google Scholar 

  19. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53–65.

    Article  CAS  PubMed  Google Scholar 

  20. Calcagno DQ, de Arrodo Cardoso Smith M, Burbano RR. Cancer type-specific epigenetic changes: gastric cancer. Methods Mol Biol. 2015;1238:79–101.

    Article  PubMed  Google Scholar 

  21. Agathanggelou A, Cooper WN, Latif F. Role of the ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497–508.

    Article  CAS  PubMed  Google Scholar 

  22. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007;17:15–22.

    Article  CAS  PubMed  Google Scholar 

  23. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, et al. Nuclear localisation and epigenetic inactivation of the ras effector/tumour suppressor RASSF2A in multiple human cancers. Oncogene. 2008;27:1805–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003;22:8999–9006.

    Article  CAS  PubMed  Google Scholar 

  25. Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, et al. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer. 2007;120:7–12.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer. 2007;120:32–8.

    Article  CAS  PubMed  Google Scholar 

  27. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, et al. RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer. 2005;93:1395–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, et al. Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci. 2008;99:958–66.

    Article  CAS  PubMed  Google Scholar 

  29. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep. 2009;22:1519–26.

    CAS  PubMed  Google Scholar 

  30. Ren J, He W, Zhang R, Li Z, Cao W, Yao J, et al. RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum alpha-fetoprotein level. J Huazhong Univ Sci Technol Med Sci. 2009;29:309–12.

    Article  CAS  PubMed  Google Scholar 

  31. Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, et al. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics. 2013;8:893–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Mezzanotte JJ, Hill V, Schmidt ML, Shinawi T, Tommasi S, Krex D, et al. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells. Epigenetics. 2014;9:1496–503.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Dr. Lutfi Kırdar Kartal Education and Research Hospital, Istanbul, Turkey

    D. Aydin & M. Aliustaoglu

  2. Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, TEM Avrupa Otoyolu, Goztepe Cikisi, No:1, Bağcılar, 34214, Istanbul, Turkey

    A. Bilici

  3. Department of Pathology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey

    S. Kayahan, D. Yavuzer & M. Basar

Authors
  1. D. Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bilici
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Kayahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Yavuzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Basar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Aliustaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bilici.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aydin, D., Bilici, A., Kayahan, S. et al. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy. Clin Transl Oncol 18, 608–616 (2016). https://doi.org/10.1007/s12094-015-1405-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1405-9

Keywords

Search

Navigation